Loading…
Employees: 179
Size Puma Biotechnology (PBYI) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $426M, the 2809th largest of 3,117 United States companies the cockpit tracks. Shares closed at $8.25 on 6 Nov 2026.
Performance Over six months the shares gained 10.2%, against -15.9% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue fell 2.9% over the last twelve months (peer median +9.3%); the operating margin is 13.2% (peer median 2.4%).
Valuation It trades at 21.7× forward earnings against a peer median of 20.0× (4th most expensive of 9).
Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 36.9 points above its cost of capital (11.7% WACC).
Short interest Short interest is 8.8% of the free float (15 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $231M | $228M | $230M | $236M | $228M |
| Revenue growth | — | -1% | -2% | +3% | — |
| Gross profit | $173M | $170M | $166M | $173M | $173M |
| EBITDA | $40.8M | $48.2M | $42.5M | $44.8M | $39.6M |
| Net income | $26.7M | $31.1M | $30.3M | $21.6M | $2,000 |
| Free cash flow | $41.2M | $41.7M | $38.9M | $26.9M | -$15.8M |
| Capital expenditure | -$10,000 | $71,000 | $56,000 | $12.6M | $0 |
| Total debt | $4.82M | $28.5M | $74.1M | $111M | $114M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PBYI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -17.2% | -11.7% | 6th lowest of 21 |
| 6-month return | +10.2% | -15.9% | 3rd highest of 20 |
| Distance from 52-week high | -28.3% | -37.4% | 7th highest of 21 |
| Revenue growth (TTM) | -2.9% | +9.3% | 8th lowest of 19 |
| Operating margin | 13.2% | 2.4% | 4th highest of 19 |
| Forward P/E | 21.7× | 20.0× | 4th most expensive of 9 |
| Growth the price implies (Req g, 7 yrs) | 2.8% | 3.1% | 5th least demanding of 9 |
| Growth delivered (Del g) | +0.3% | +11.7% | lowest of 9 |
| Hurdle (Req g minus delivered) | +2.5 pp | -10.2 pp | 3rd most demanding of 9 |
| ROIC minus cost of capital | +36.9 pp | -2.2 pp | highest of 17 |
| EV / EBITDA | 8.3× | 14.0× | 3rd cheapest of 9 |
| Net debt / EBITDA | -2.2× | 0.3× | 2nd least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Puma Biotechnology PBYI | United States | $426M | +10% | -3% | 13% | 21.7× | 2.8% | +0.3% |
| Dong-A Socio 000640.KS | South Korea | $425M | -11% | +10% | 7% | 7.6× | -8.8% | +12.8% |
| Phathom Pharmaceuticals PHAT | United States | $427M | -57% | +87% | -9% | 24.2× | n/a | n/a |
| Lifecome Biochemistry 002868.SZ | China | $428M | -51% | -24% | -6% | n/a | n/a | n/a |
| BlossomHill Therapeutics BLSM | United States | $429M | n/a | n/a | n/a | n/a | n/a | n/a |
| Beijing Centergate Technologies (Holding) 000931.SZ | China | $430M | -20% | -16% | 2% | 21.2× | 9.9% | +6.7% |
| Aarti Drugs AARTIDRUGS.NS | India | $430M | +12% | +15% | 11% | 18.9× | 19.7% | +3.5% |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $432M | -44% | -8% | -23% | n/a | n/a | n/a |
| Relmada Therapeutics RLMD | United States | $416M | -47% | n/a | n/a | n/a | n/a | n/a |
| Assembly Biosciences ASMB | United States | $416M | -31% | +125% | -12% | n/a | n/a | n/a |
| Jiangxi Synergy Pharmaceutical 300636.SZ | China | $414M | -16% | -2% | 3% | 54.8× | n/a | n/a |
| Anhui Sunhere Pharmaceutical Excipients 300452.SZ | China | $412M | -16% | +9% | 19% | 14.4× | -4.5% | +12.1% |
| Shaanxi Panlong Pharmaceutical 002864.SZ | China | $411M | -13% | -9% | 9% | n/a | -0.4% | +11.2% |
| Synmosa Biopharma 4114.TWO | Taiwan | $442M | +2% | +11% | 11% | n/a | 6.5% | +15.3% |
| Hansa Biopharma HNSA.ST | Sweden | $410M | +39% | -4% | -304% | n/a | n/a | n/a |
| RPG Life Sciences RPGLIFE.NS | India | $448M | +2% | +12% | 18% | n/a | n/a | n/a |
| Shandong Sinobioway Biomedicine 002581.SZ | China | $404M | -40% | +91% | -65% | n/a | n/a | n/a |
| Evolus EOLS | United States | $449M | +7% | +14% | -7% | 27.4× | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $450M | +4% | -21% | 8% | n/a | 23.7% | +28.2% |
| Shanghai Fudan Forward S&T 600624.SS | China | $450M | -4% | -14% | -34% | n/a | n/a | n/a |
| JW Pharmaceutical 001060.KS | South Korea | $402M | -28% | +10% | 14% | 6.2× | -16.9% | +7.2% |